[A19-59] Ravulizumab - Benefit assessment according to §35a Social Code Book V
Last updated 04.11.2019
Project no.:
A19-59
Commission:
Commission awarded on 01.08.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Haematology
Adults with paroxysmal nocturnal haemoglobinuria (PNH)
Added benefit neither proven for patients with haemolysis and at least one clinical symptom indicative of high disease activity nor for clinically stable patients after at least 6 months of eculizumab treatment
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-104 | Ravulizumab (paroxysmal nocturnal haemoglobinuria) - Addendum to Commission A19-59 | Commission completed |